Axcel has signed an agreement to aquire a majority ownership stake in AddPro, a Swedish leading provider of IT and cloud services. AddPro’s current management team and founders will reinvest in the company alongside Axcel.

AddPro was founded 2000 in Malmö and has a total approximate revenue of SEK 800 million and close to 350 employees. AddPro is acquired from Adelis Equity Partners, founders, the management team and key employees. The transaction is subject to customary regulatory approvals. AddPro is the second investment in Axcel VI.

Vinge’s team consisted of partners Christina Kokko (M&A) and Mikael Ståhl (Banking & Finance) and associates Johanna Wiberg, Stina Bengtsson and Carl Fredrik Wachtmeister (M&A), Linn Adewald, Pauline Lagerstrand, Elias Lundin and Jolinn Uhlin (Banking & Finance), Mathilda Persson, Martin Boström and Fredrika Hjelmberg (Commercial Agreements & IT), Ilze Lukins and Anna Li (IP), Lisa Hörnqvist (GDPR), Veronika Garemark (Employment), Kristoffer Larsson (Real Estate), Kristoffer Sällfors (Public Procurement), Johan Wahlbom (Antitrust) and Nathalie Hughes (VDR assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024